Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 78Leukemia, Lymphocytic, Chronic, B-Cell 77Leukemia 77Myelodysplastic Syndromes 61Lymphoma 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Multiple Myeloma 46Lymphoma, Non-Hodgkin 45Hodgkin Disease 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Hematologic Neoplasms 27Melanoma 26Recurrence 20Lymphoma, Follicular 18Lymphoma, Mantle-Cell 17Myeloproliferative Disorders 16Graft vs Host Disease 15Primary Myelofibrosis 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell 13Neoplasms, Plasma Cell 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myelomonocytic, Chronic 10Anemia, Aplastic 10Neoplasms 9Hematologic Diseases 9Neoplasm Metastasis 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Ovarian Neoplasms 7

Interventions

Sorafenib 42Bevacizumab 16Oxaliplatin 13Radiosurgery 10Gemcitabine 10Doxorubicin 10Capecitabine 10Leucovorin 9Hepatectomy 9Fluorouracil 9Cisplatin 9Radiofrequency Ablation 8Nivolumab 8pembrolizumab 7Drug Therapy 7Carboplatin 7Irinotecan 6Cryosurgery 6Talaporfin 5Mitomycin 5Everolimus 5Erlotinib Hydrochloride 5Electroporation 5spartalizumab 4Sunitinib 4Melphalan 4Ipilimumab 4Epirubicin 4Embolization, Therapeutic 4regorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Neoplasms × fludarabine × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡